NervGen Pharma Corp. (NGEN) Stock Forecast
NGEN analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.57 / 5 from 7 analysts
- Price target
- $10.00 average of analyst targets
- Upside to target
- +528.9% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.05
- 52-week range
- $1.56 – $5.97
NGEN analyst ratings
7 analystsNumber of analysts at each rating.
NGEN price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
NGEN earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.10 | −$0.10 | −$0.10 | — | — | 1 |
| Current fiscal year (2026) | −$0.49 | −$0.49 | −$0.49 | −$0.44 | −12.6% | 1 |
| Next fiscal year (2027) | −$0.34 | −$0.40 | −$0.27 | −$0.49 | +31.2% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
NGEN revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 5 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 5 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 5 |
NGEN EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
NGEN EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.07 | −$0.08 | −$0.11 | −$0.11 | −$0.10 | +43.8% | 0 up · 0 down |
| Current fiscal year (2026) | −$0.26 | −$0.27 | −$0.50 | −$0.50 | −$0.49 | +88.1% | 0 up · 0 down |
| Next fiscal year (2027) | −$0.38 | −$0.32 | −$0.34 | −$0.34 | −$0.34 | −10.8% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
NGEN earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; NGEN beat in 2 of 6.
What analysts expect from NGEN
7 analysts cover NervGen Pharma; their consensus rating is strong buy (4.57 on a 1–5 scale, where 5 is a strong buy). The average price target is $10.00, 528.9% above the latest close of $1.59. Analysts expect earnings of −$0.49 per share for 2026, −12.6% from a year earlier. For 2027 the average estimate is −$0.34 per share. NervGen Pharma beat the EPS estimate in 2 of the last 6 quarters.
Related: NGEN income statement, NGEN key metrics, NGEN chart. See the NGEN stock overview for the latest quote and news.
NGEN forecast FAQ
What is NervGen Pharma's price target?
The average analyst price target for NervGen Pharma is $10.00, 528.9% above the latest close of $1.59.
Is NervGen Pharma a buy, hold or sell?
Of 7 analysts covering NervGen Pharma, 4 rate it a strong buy, 3 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is NervGen Pharma's EPS forecast?
Analysts forecast −$0.49 per share for 2026 (range −$0.49 to −$0.49); for 2027 the estimate is −$0.34.
When does NervGen Pharma report earnings?
NervGen Pharma is expected to report results for the quarter ending September 30, 2026 on November 12, 2026; the EPS estimate is $-0.05.
Does NervGen Pharma usually beat earnings estimates?
NervGen Pharma reported EPS at or above the analyst estimate in 2 of the last 6 quarters.